Company intelligence / Profile preview

Threshold Impact

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Threshold Pharmaceuticals advanced HAP technology including evofosfamide into pivotal Phase 3 trials for soft tissue sarcoma and advanced pancreatic cancer in partnership with Merck KGaA; pipeline development for additional tumor types was in Phase 2. No recent clinical results available, and development appears discontinued post-2017.[1][3][5]

Therapeutic areas: OncologyMen's Health
Modalities: Small moleculeHypoxia-activated prodrug
Industry: Biotech

Partnerships

Merck KGaA (Darmstadt, Germany)Sarcoma Alliance for Research through Collaboration (SARC)Pfizer (historical partner)

Beyond the preview

Go deeper on Threshold Impact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Threshold Impact.

Explore the full profile